Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 13 Billion | USD 20 Billion | 5% | 2023 |
The global colorectal cancer market size was evaluated at $13 billion in 2023 and is slated to hit $20 billion by the end of 2032 with a CAGR of nearly 5% between 2024 and 2032.
Colorectal cancer, which is also referred to as bowel cancer, rectal cancer, and colon cancer, takes place in the rectum or colon. For the record, it is the second leading cause of death due to cancer in the U.S. Moreover, this kind of cancer occurs through a growth referred to as a polyp taking place in the interior side of the colon. Reportedly, colorectal cancer can be cured when localized to the bowel.
A surge in the incidences of colorectal cancer patients to prop up the global market trends
An increase in the cases of colorectal cancer and breakthroughs in cancer treatment is anticipated to propel the expansion of the global colorectal cancer market. Surging awareness about detecting colorectal cancer in the early phase is likely to augment the growth of the market across the globe.
Moreover, the geriatric population is prone to colorectal cancer, and this can provide impetus to the expansion of the market across the globe. Launching new medicines for treating colorectal cancer can proliferate the global market size. Supportive government initiatives will further drive the global market trends.
A rise in the use of liquid biopsies, immunotherapy, and targeted drug treatments will sketch a profitable roadmap for the global market. Need for minimally invasive surgeries, including robotic surgeries and endoscopic surgeries, is projected to boost the market expansion globally. Use of digital health tools for checking patient health and the demand for telemedicine consulting services will drive the business space.
Escalating costs of cancer treatment can pose a huge obstacle in the global industry expansion over 2024-2032
Surging prices of treating colorectal cancer and low awareness about colorectal cancer therapies are likely to negatively impact the expansion of the global colorectal cancer industry. Furthermore, side effects of treating colorectal cancer can further hinder the global industry surge in the ensuing years.
Utilization of combined drug therapies for cancer treatment can open new growth avenues for the global market
Growing focus on early identification of colorectal cancer and the use of artificial intelligence techniques for assessing medical images will create new facets of growth for the global colorectal cancer market. Development of targeted treatments that target genetic mutations is likely to propel the global market expansion.
In addition to this, the exploration of new combined drug treatments for colorectal cancer to overcome drug resistance, along with the need to improve clinical outcomes of the drug treatment on subjects, is predicted to enlarge the scope of the growth of the global market.
Lack of reimbursement policies can challenge the global industry expansion over assessment period
Low compensation and regulatory hurdles faced by pharmaceutical firms can deter the expansion of the global colorectal cancer industry. Less access to high-quality healthcare facilities in rural regions can challenge the global industry surge in the ensuing years.
The global colorectal cancer market is divided into treatment type, end-user, diagnostics type, and region.
In terms of treatment type, the colorectal cancer market across the globe is segmented into chemotherapy, immunotherapy, radiation therapy, targeted therapy, and surgery segments. Apparently, the immunotherapy segment, which gathered nearly 55% of the global market earnings in 2023, is expected to record the fastest CAGR in the coming few years as immunotherapy helps the immune system of the human body in combating cancer.
Based on end-user, the global colorectal cancer industry is segmented into hospitals & clinics, academic research institutes, and home care settings segments.
Apparently, the hospitals & clinics segment, which led the global industry size in 2023, is prognosis to account majorly towards the segmental expansion in the assessment period. This can be a result of the comprehensive range of services offered by hospitals & clinics, such as chemotherapy, patient care, diagnosis, and surgery.
On the basis of diagnostics type, the global colorectal cancer industry is divided into CT scan, colonoscopy, MRI, stool tests, and flexible sigmoidoscopy segments. Moreover, the colonoscopy market, which led the global market share in 2023, is likely to lead the global market expansion in the forecast timespan.
The segmental surge in the coming eight years can be a result of the ability of colonoscopy in the early identification of precancerous polyps that help prevent cancer by removing it. Apart from this, it helps in apt visualization of the rectum and colon, which will help in the perfect identification of cancer cells in the human body.
Report Attributes | Report Details |
---|---|
Report Name | Colorectal Cancer Market |
Market Size in 2023 | USD 13 Billion |
Market Forecast in 2032 | USD 20 Billion |
Growth Rate | CAGR of 5% |
Number of Pages | 219 |
Key Companies Covered | Bristol-Myers Squibb Company, Eli Lilly and Company, Bayer AG, F. Hoffmann-La Roche Ltd., Guardant Health Inc., Mainz Biomed NV, Amgen Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Exact Sciences Corporation, Danaher Corporation, Novigenix SA., and others. |
Segments Covered | By Treatment Type, By End-User, By Diagnostics Type, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is likely to maintain leading status in the global market over the analysis period
North America, which accounted for about 64.3% of the global colorectal cancer market size in 2023, is predicted to establish a leading position in the global market in the forecasting timeline. Furthermore, the regional market elevation in the next decade can be owing to the presence of advanced healthcare infrastructure in nations such as Canada, and the U.S. Surging occurrence of colorectal cancer in aging populace in the region will drive the regional market surge in the coming years.
Moreover, the strong growth witnessed in the pharmaceutical sector in countries such as the U.S. is likely to bring a paradigm shift in the regional market in the foreseeable future.
The European colorectal cancer industry is slated to account for the fastest compounded growth annually in the forecast timeline. The progression of the industry in Europe can be a result of the presence of an aging population in European countries, along with massive awareness about the ailment among the European population.
Supportive government schemes promoting cancer research, along with the availability of outstanding healthcare amenities, will embellish the growth of the industry globally.
The global colorectal cancer market profiles key players such as:
By Treatment Type
By End-User
By Diagnostics Type
FrequentlyAsked Questions
Colorectal cancer, which is also referred to as bowel cancer, rectal cancer, and colon cancer, takes place in the rectum or colon
The global colorectal cancer market growth over the forecast period can be owing to a rise in the use of liquid biopsies, immunotherapy, and targeted drug treatments.
According to a study, the global colorectal cancer industry size was $13 billion in 2023 and is projected to reach $20 billion by the end of 2032.
The global colorectal cancer market is anticipated to record a CAGR of nearly 5% from 2024 to 2032.
The European colorectal cancer industry is set to register the fastest CAGR over the forecasting timeframe owing to the presence of an aging population in the European countries and massive awareness about the ailment among the European population. Supportive government schemes promoting cancer research, along with the availability of outstanding healthcare amenities, will embellish the growth of the industry globally.
The global colorectal cancer market is led by players such as Bristol-Myers Squibb Company, Eli Lilly and Company, Bayer AG, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Mainz Biomed NV, Amgen Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Genentech, Inc., Exact Sciences Corporation, Danaher Corporation, and Novigenix SA.
The global colorectal cancer market report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, cash-benefit analysis, market attractiveness analysis, sentiment analysis, PESTEL analysis, trend analysis, SWOT analysis, trade area analysis, demand & supply analysis, Porter’s five force analysis, factor analysis, and value chain analysis. It provides an apt scenario about demand and factor conditions in the country impacting the profitability of the firms in the domestic and international markets.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed